Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA

Narciso, Ana Rita; Iovino, Federico; Thorsdottir, Sigrun; Mellroth, Peter; Codemo, Mario; Spoerry, Christian; Righetti, Francesco; Muschiol, Sandra; Normark, Staffan; Nannapaneni, Priyanka; Henriques‐Normark, Birgitta

doi:10.1073/pnas.2122386119

Cited by 14 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the prediction, 24 potential vaccine candidates including multiple outer membrane and secretory proteins were picked out. Among these proteins, ABC transporters are essential proteins that exist in almost all living organisms 25 , which have been identified as potential protective antigens 14,26 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Novel antigenic proteins of Mycoplasma synoviae as potential vaccine candidates

Shi

Han

et al. 2023

Preprint

View full text Add to dashboard Cite

Mycoplasma synoviae (M. synoviae) is a serious avian pathogen causing severe economic losses to chicken and turkey producers worldwide. The currently available live attenuated vaccine and inactivated vaccine on the market elicit only limited protection. The aim of this study was to identify antigenic proteins of M. synoviae as potential subunit vaccine candidates. In immunoproteomics and reverse vaccinology analyses, a total 24 candidate antigens were picked out. Five candidate antigens were selected to evaluate immunogenicity and preliminary protection in a chicken model, including RS01790 (lipoprotein, putative sugar ABC transporter), BMP (BMP family ABC transporter substrate-binding protein), GrpE (nucleotide exchange factor), RS00900 (putative nuclease) and RS00275 (Uncharacterized protein). The results showed that the five antigens had good immunogenicity. They could be localized on the M. synoviae cell membrane and adhere to DF-1 cells using indirect immunofluorescence assay. They induced specific humoral and cellular immune responses. Vaccine efficacy was evaluated by observing weight gain, pathogen load, pathological changes. As a result, the vaccinated chickens revealed significantly higher body weight gain, with lower air sac lesion scores and tracheal mucosal thicknesses. The vaccinated chickens also showed lower M. synoviae loads in throat swabs than nonvaccinated chickens. The protective effect of BMP, GrpE and RS00900 vaccines is better than that of RS01790 and RS00275. In conclusion, our study demonstrates the potential of using subunit vaccine, providing new ideas for the development of M. synoviae vaccines. The vaccine candidates may contribute to the future development of therapeutic strategies to control the spread of M. synoviae worldwide.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Immunoproteomics is one of the best powerful methods to identify antigens 13 . It has been demonstrated that RV is an extremely effective method for quickly identifying novel vaccine targets 14 .…”

Section: Introductionmentioning

confidence: 99%

Novel antigenic proteins of Mycoplasma synoviae as potential vaccine candidates

Shi

Han

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…One hour p.i, the supernatant and non-adherent cells were removed by aspiration, washing three times with fresh PBS. Infection media was added to the wells with adherent cells followed by 100µg/ml of gentamicin, a dose shown to kill extracellular pneumococci in this assay ( 27 , 28 ), including ST3 ( 29 – 31 ). Plates were further incubated for 30 minutes at 37°C in 5% CO 2 with gentle horizontal shaking 50rpm.…”

Section: Methodsmentioning

confidence: 99%

Intracellular survival of Streptococcus pneumoniae in human alveolar macrophages is augmented with HIV infection

et al. 2022

View full text Add to dashboard Cite

People Living with HIV (PLHIV) are at an increased risk of pneumococcal pneumonia than HIV-uninfected adults, but the reasons for this are still not well understood. We investigated whether alveolar macrophages (AM) mediated control of pneumococcal infection is impaired in PLHIV compared to HIV-uninfected adults. We assessed anti-bactericidal activity against Streptococcus pneumoniae of primary human AM obtained from PLHIV and HIV-uninfected adults. We found that pneumococcus survived intracellularly in AMs at least 24 hours post ex vivo infection, and this was more frequent in PLHIV than HIV-uninfected adults. Corroborating these findings, in vivo evidence showed that PLHIV had a higher propensity for harboring S. pneumoniae within their AMs than HIV-uninfected adults. Moreover, bacterial intracellular survival in AMs was associated with extracellular propagation of pneumococcal infection. Our data suggest that failure of AMs to eliminate S. pneumoniae intracellularly could contribute to the increased risk of pneumococcal pneumonia in PLHIV.

show abstract

“…The efficacy of the current vaccine limitation is attributed to the emergence and switching of serotypes ( 8 , 9 ). Hence, an alternative noncapsule surface virulence factor(s) (protein)-based vaccine approach has gained importance ( 10 , 11 ). Nevertheless, among several pneumococcal virulence factors ( 6 , 12 ), the polysaccharide capsule (CPS) is still recognized as the major virulence factor ( 13 – 15 ), and pneumococcal colonization is the critical determining step in pneumococcal diseases ( 6 , 14 , 16 ).…”

Section: Introductionmentioning

confidence: 99%